Financial Performance - The company reported a revenue of ¥274,201,797.20 for 2022, a decrease of 8.86% compared to the previous year[3]. - Net profit attributable to shareholders was ¥34,720,762.18, down 17.17% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥31,115,942.64, reflecting a decline of 22.15%[5]. - Basic earnings per share decreased to ¥0.46, a drop of 36.99% from the previous year[5]. Assets and Equity - Total assets at the end of the reporting period reached ¥442,298,206.94, an increase of 105.12% year-on-year[5]. - Shareholders' equity attributable to the company was ¥391,536,339.84, up 172.40% compared to the beginning of the year[5]. - The company issued 18,085,981 new shares in December 2022, which diluted earnings per share[7]. Impact Factors - The decline in performance was primarily due to the impact of COVID-19 and power restrictions in Chengdu during the summer[6]. Strategic Focus - The company is focusing on technological innovation and expanding new products and markets to enhance its core competitiveness[6]. Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the annual report[8].
欧康医药(833230) - 2022 Q4 - 年度业绩